Research into the efficacy of GLP-1 drugs found that, in a clinical trial setting, Semaglutide (Ozempic and Wegovy) could result in a 14.9% reduction in body weight over the course of 68 weeks
& Boutros, M
Though the rapid growth of Tirzepatide is evident, against the backdrop of its base, S-drug's prescription volume and market share still hold a dominant advantage
Semaglutide has demonstrated numerous benefits in clinical trials, including: Weight loss Diabetes management Cardioprotective effects Improved overall metabolic health Its remarkable ability to induce significant weight loss has generated considerable interest among medical experts and individuals struggling with weight-related issues
The GLP-1 agonists used were liraglutide (57.3%), followed by semaglutide (32.9%), dulaglutide (4.9%), exenatide (4.1%), and lixisenatide (0.9%)
This is a once per week injection with a tiny insulin needle